The Boston Red Sox hosted Cure Alzheimer’s Fund at a recent baseball game against the Detroit Tigers to raise awareness about Alzheimer’s and bring attention to the nonprofit group’s support for research into new treatments and ways of preventing or curing this disease. The event included a ceremony…
Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key…
June is World Alzheimer’s and Brain Awareness Month, and James E. Galvin, MD, MPH, a leading neuroscientist and associate dean at Florida Atlantic University’s Charles E. Schmidt College of Medicine, has compiled a list of myths and truths about the disease. According to Galvin, some…
Medications for type 2 diabetes may help treat symptoms of Alzheimer’s, as these two conditions share common disease mechanisms, according to recent research. Fernanda De Felice, PhD, an associate professor at Federal University Rio de Janeiro, Brazil presented her team’s findings, titled “Molecular connections between Alzheimer’s disease and Type 2 diabetes,”…
Cognition Therapeutics has received two multi-year grants from the National Institute on Aging (NIA) totaling $6.6 million to fund two clinical studies of Elayta (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. Elayta is a brain-penetrating small molecule with a unique disease-modifying mechanism of…
A Phase 1 trial to evaluate the safety and effectiveness of Longeveron’s allogeneic mesenchymal stem cells (LMSCs) in patients with Alzheimer’s disease is currently looking for participants, the biopharmaceutical company announced. Eligible participants must be between 50 and 80 years old, with a confirmed diagnosis of Alzheimer’s disease…
UsAgainstAlzheimer’s recently launched the Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) initiative as a groundbreaking partnership between the public and private sectors to identify and prioritize the needs and preferences of those living with Alzheimer’s disease. The organization recently held a webinar to present the AD…
A new Facebook app can provide emotional support to unpaid caregivers of Alzheimer’s disease patients, according to a study. Researchers at Indiana University Purdue University Indianapolis developed the app as part of an investigation that looked at “friendsourcing” as a type of peer support group intervention. In particular, they wanted to…
Janssen pulled the plug on a Phase 2b/3 trial and a Phase 2 safety study of its Alzheimer’s disease experimental therapy atabecestat due to toxicity issues as a result of serious elevations in liver enzymes seen in some study participants. Atabecestat is a BACE inhibitor, intended to…
Alkahest‘s Phase 2 clinical trial testing GRF6019 — an experimental blood-derived protein — in patients with mild to moderate Alzheimer’s disease has dosed its first participant, the company recently announced. The trial (NCT03520998), which will assess the safety, tolerability, and feasibility of GRF6019, is still recruiting participants. Researchers expect…
Get regular updates to your inbox.